查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922965

人脑模型市场：2026-2032年全球预测（依疾病模型、技术、应用和最终用户划分）

Human Brain Models Market by Disease Model, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人脑模型市场价值将达到 2.1345 亿美元，到 2026 年将成长至 2.4333 亿美元，到 2032 年将达到 5.6782 亿美元，复合年增长率为 15.00%。

关键市场统计数据
基准年 2025 2.1345亿美元
预计年份：2026年 2.4333亿美元
预测年份 2032 5.6782亿美元
复合年增长率 (%) 15.00%

人脑模型技术作为转化神经科学和治疗发展的重要组成部分，其策略背景和必要性值得探讨。

人脑模型如今在神经科学、生物技术和转化医学的交叉领域扮演核心角色，迫使各机构重新思考如何建构其临床前研究和药物发现流程。本文将此主题置于更广泛的多学科领域背景下进行探讨，该领域中组织工程、计算建模和微加工技术的进步正在催生新的实验范式。本文旨在帮助读者理解这些技术对药物发现、神经机制研究、个人化医疗和安全性评估的战略意义，并强调决策者为何必须对这些技术有深入的了解。

识别将重塑人脑模型研究和转化整合的技术、制度和监管转折点

人类脑模型研究领域正经历着一场变革性的转变，其驱动力包括技术的成熟、跨学科的融合以及相关人员期望的转变。先进的生物製造和类器官培养等技术催化剂使得构建生理相关性更高的模型成为可能，而微流体系统和神经介面则提高了实验控制的精确度和数据密度。同时，计算模拟模型透过提供可扩展的假设生成和整合分析，对湿实验室系统起到了补充作用，从而构建了一个物理模型和虚拟模型共同演化的混合生态系统。

分析 2025 年引入关税后供应链限制和政策因应措施对整个研究生态系统采购、合作和营运的系统性调整的影响。

2025年关税及贸易政策调整对支持人脑模型研究的生态系统产生了多方面的影响。特殊试剂、生物材料、精密加工设备和微流体组件的供应链均受到不同程度的干扰，迫使采购团队重新评估筹资策略。为此，各机构已开始评估替代供应商，尽可能在地采购，并调整库存政策，以保护正在进行的研究免受突发中断的影响。这些营运应对措施已成为业务永续营运计画的重要组成部分。

整合按模型类型、应用领域、最终用户、技术和疾病模型分類的细分，以製定有针对性的开发和转化研究的优先策略。

透过辨识技术能力与使用者需求的交集，可以建构更精细的细分框架，从而实现更精确的策略规划。基于模型类型，该领域涵盖：3D列印结构（包括基于生物墨水的模型）；动物模型（涵盖猪、灵长类动物和囓齿类动物系统）；计算模型（In Silico模型）；干细胞衍生系统（包括胚胎干细胞、诱导多能干细胞和神经干细胞平台）；以及涵盖微流体和类器官相容形式的合成结构。每类模型都有其自身的检验挑战和价值提案。使用生物墨水的3D列印组织强调结构保真度和扩充性，而动物模型则提供了成熟的生理复杂性，可用于物种间比较。In Silico模型能够快速探索参数和建构机制假设，而干细胞平台则能够展现不同成熟阶段的人类细胞的相关性。最后，合成微流体和类器官系统将可控性与独特的人类生物学特性结合。

识别区域优势、监管差异和创新生态系统将决定全球市场的策略切入点和合作路径。

区域动态是策略定位的核心，因为不同地区的创新生态系统、法规环境和生产能力差异显着。在美洲，强大的转化研究基础、密集的临床试验中心网络以及成熟的生物技术资金筹措环境，支持了从发现到早期临床检验的快速进展。该地区还拥有成熟的生物製造能力和丰富的经验丰富的神经科学家人才储备，这些优势共同促进了产业界和学术界相关人员之间的伙伴关係，并推动了原型平台向检验服务的规模化转化。

评估决定空间领导地位和扩充性的竞争策略、平台差异化、伙伴关係模式和创新策略

在人脑模型领域，各公司之间的竞争动态集中在平台差异化、服务广度以及透过检验研究和外部合作来证明其转化应用价值的能力。主要企业强调模组化平台，让客户可以根据疾病重点、分析输出和通量来配置模型，从而满足学术界和商业用户多样化的研究需求。与学术机构和临床联盟建立策略伙伴关係，是提升信誉度并实现平台表现与既定生物学终点指标对标的重要手段。

实施稳健的采购流程、协同检验、模组化产品架构和多学科人才策略，以加速产品推广应用并降低开发风险。

领导者应采取一系列切实可行的措施，使技术能力与组织目标和市场实际情况保持一致。首先，应优先考虑供应链韧性，具体措施包括：为关键试剂和组件建立双源筹资策略、选择区域供应商以及建立紧急库存，以最大限度地减少中断。这种战术性转变将降低营运风险，并即使在面临外部衝击的情况下，也能维持研发进度的可预测性。

我们将展示一种严谨的混合调查方法，该方法整合了专家访谈、文献和专利研究、技术准备评估和检验研讨会。

本分析的调查方法结合了定性和定量方法，以确保其稳健性和实用性。主要研究包括对各类利害关係人进行结构化访谈，其中包括资深学术研究人员、製药和生物技术公司的研发总监、专业合约研究机构的负责人、医疗器材开发人员和监管相关人员。这些访谈从多个观点深入探讨了技术采纳的驱动因素、检验要求和采购时间表。

整合策略要务和营运重点，以确定哪些组织能够将人脑模型创新转化为永续的临床和商业性价值。

总之，人脑模型是一套变革性的工具，正在重塑神经科学解决问题的方式，并在临床开发前降低治疗策略的风险。该领域的特点是技术快速融合、监管要求不断演变以及商业模式的转变，这些都旨在评估可证实的转化相关性。投资于检验、互通性和供应链韧性的相关人员将更有利于把平台进步转化为具有临床意义的成果。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依疾病模型分類的人脑模型市场

  • 阿兹海默症
  • 癫痫
  • 帕金森氏症
  • 中风

9. 按技术分類的人脑模型市场

  • 生物製造
  • 微流体技术
    • 液滴微流体技术
    • 晶片上的器官
  • 神经介面
    • 体外电生理学
    • 体内记录
  • 类器官培养
    • 鹰架底座
    • 无支架

第十章 人类脑模型市场依应用领域划分

  • 药物发现
    • 高通量筛检
    • 先导药物最适化
  • 神经科学研究
    • 阿兹海默症研究
    • 帕金森氏症调查
    • 中风研究
  • 个人化医疗
  • 毒性测试

第十一章 以最终用户分類的人脑模型市场

  • 学术机构
    • 研究所
    • 大学
  • CRO（受託研究机构）
  • 医院和诊所
  • 製药和生物技术公司
    • 大型製药企业
    • 中小型生技公司

第十二章 人类大脑模型市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 人类脑模型市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国人脑模型市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国人类大脑模型市场

第十六章 中国的人脑模型市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3D Systems, Inc.
  • Anatomy Warehouse, LLC
  • Brainlab AG
  • EISCO Scientific
  • ESP Models
  • GE HealthCare Technologies Inc.
  • Global Plastics, Inc.
  • GPI Anatomicals
  • Koninklijke Philips NV
  • Materialise NV
  • Medtronic plc
  • Organovo Holdings, Inc.
  • Scientific Accessories, Inc.
  • Siemens Healthineers AG
  • SmartLabs Education Ltd.
  • Stratasys Ltd.
  • Stryker Corporation
Product Code: MRR-867BED9A9E8A

The Human Brain Models Market was valued at USD 213.45 million in 2025 and is projected to grow to USD 243.33 million in 2026, with a CAGR of 15.00%, reaching USD 567.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 213.45 million
Estimated Year [2026] USD 243.33 million
Forecast Year [2032] USD 567.82 million
CAGR (%) 15.00%

Establishing strategic context and imperatives for human brain model technologies as indispensable components of translational neuroscience and therapeutic development

Human brain models now occupy a central role at the intersection of neuroscience, biotechnology, and translational medicine, prompting organizations to reassess how preclinical and discovery pipelines are constructed. This introduction positions the topic within a broader context of converging disciplines where advances in tissue engineering, computational modeling, and microfabrication are enabling new experimental paradigms. The intent here is to orient readers to the strategic relevance of these technologies for drug discovery, mechanistic neuroscience, personalized medicine, and safety assessment, emphasizing why a refined understanding is essential for decision-makers.

Across institutions and commercial entities, the impetus to adopt complex human-relevant systems has shifted from academic curiosity to operational necessity. Researchers and R&D leaders face mounting pressure to reduce late-stage failure, accelerate translational fidelity, and meet increasingly stringent ethical and regulatory expectations. Consequently, the adoption of human brain models is driven by scientific imperatives and institutional risk management, with significant implications for platform selection, partnership formation, and investment prioritization.

As we progress through this executive summary, readers will encounter a synthesis of technological trends, segmentation dynamics, regional attributes, and tactical recommendations. The following sections are designed to provide a compact yet substantive foundation for executives and technical leaders who must align organizational strategy to a rapidly evolving research landscape, while also anticipating regulatory and supply chain shifts that influence adoption trajectories.

Identifying pivotal technological, institutional, and regulatory inflection points reshaping human brain model research and translational integration

The landscape for human brain models is undergoing transformative shifts driven by technological maturation, interdisciplinary integration, and evolving stakeholder expectations. Technological catalysts such as advanced biofabrication and organoid culture are enabling increasingly physiologically relevant constructs, while microfluidic systems and neural interfaces are improving experimental control and data density. Concurrently, computational in silico models complement wet-lab systems by providing scalable hypothesis generation and integrative analyses, creating a hybrid ecosystem where physical and virtual models co-evolve.

Institutional behavior is adapting to these capabilities. Academic laboratories are forming translational consortia with industry partners to accelerate validation and standardization, and contract research organizations are expanding service portfolios to include model development and qualification services. Funding bodies and private investors have reoriented priorities toward platforms that promise higher translational fidelity, with an emphasis on human-relevant endpoints. These shifts are reinforcing a move away from single-model reliance toward diversified model stacks tailored to specific research questions.

Regulatory and ethical considerations are also reshaping the field. Guidance frameworks and ethics discourse now prioritize reproducibility, data transparency, and humane research practices, incentivizing the adoption of validated alternatives to traditional animal testing. As a result, organizations that proactively align technology development with regulatory expectations and ethical standards gain first-mover advantages in collaboration, market access, and stakeholder trust. Taken together, these transformative shifts underscore a trajectory in which integration, validation, and interoperability become the primary determinants of long-term impact.

Analyzing how 2025 tariff-driven supply chain constraints and policy responses are prompting systemic procurement, partnership, and operational adjustments across the research ecosystem

The imposition of tariffs and trade policy adjustments in 2025 has produced multifaceted effects on the ecosystem that supports human brain model research. Supply chains for specialized reagents, raw biomaterials, precision fabrication equipment, and microfluidic components have been disrupted in varying degrees, prompting procurement teams to reassess sourcing strategies. In response, organizations have begun to evaluate alternative suppliers, localize critical inputs where feasible, and adjust inventory policies to insulate ongoing research from episodic disruptions. These operational responses have become integral to continuity planning.

Secondary effects are visible in the structure of commercial partnerships and procurement frameworks. International collaborators are negotiating new terms to accommodate customs complexity, delayed lead times, and the administrative burden of cross-border shipments. Consequently, some consortia have shifted toward onshore manufacturing or regional distribution hubs to reduce exposure to customs volatility. While these adaptations enhance resilience, they also necessitate upfront investment in qualification and vendor audits, altering cost and timeline calculations for model development projects.

Furthermore, policy shifts have influenced strategic decisions around technology transfer and intellectual property management. Entities pursuing collaborative research are placing greater emphasis on contractual clarity related to responsibilities for export compliance and tariff-related contingencies. This has led to more conservative timelines for multicenter validations and a preference for modular project designs that can tolerate phased component deliveries. Collectively, these dynamics are shaping how organizations prioritize projects, select suppliers, and structure international collaborations within the human brain model ecosystem.

Integrating model type, application, end-user, technology, and disease-model segmentation to inform targeted development and translational prioritization strategies

A nuanced segmentation framework reveals where technological capability and user need intersect, enabling more precise strategic planning. Based on model type, the field encompasses 3D printed constructs that include bioink-based approaches, animal models spanning porcine, primate, and rodent systems, computational or in silico models, stem cell-derived systems comprising embryonic stem cell, induced pluripotent stem cell, and neural stem cell platforms, and synthetic constructs that cover microfluidic and organoid-enabled formats. Each model class presents distinct validation challenges and value propositions: bioink-based 3D printed tissues emphasize architectural fidelity and scalability; animal models offer established physiological complexity for cross-species comparison; in silico models provide rapid parameter sweeps and mechanistic hypotheses; stem cell platforms deliver human cellular relevance with varying maturation states; and synthetic microfluidic and organoid systems bridge control with human-specific biology.

Application segmentation further clarifies demand patterns, with drug discovery activities driven by high throughput screening and lead optimization, neuroscience research targeted at Alzheimer's, Parkinson's, and stroke studies, personalized medicine focusing on patient-derived model systems, and toxicology testing requiring standardized, reproducible assay formats. These application domains influence platform selection and throughput expectations; for example, high throughput screening favors scalable, plate-compatible model formats, whereas Alzheimer's research often demands long-term culture stability and complex cellular interactions.

End users shape commercial and service models, as academia represented by research institutes and universities emphasizes exploratory innovation and protocol openness, contract research organizations prioritize turnkey service delivery and regulatory alignment, hospitals and clinics seek clinically actionable readouts integrated with patient care workflows, and pharma and biotech companies including large pharmaceutical firms and small or mid-size biotech entities focus on translational endpoints and portfolio de-risking. These distinctions determine procurement cycles, validation rigor, and willingness to invest in bespoke model development.

Technology segmentation highlights core enablers: biofabrication with 3D bioprinting supports structural complexity; microfluidics including droplet microfluidics and organ-on-chip architectures enable dynamic microenvironments; neural interfaces that span in vitro electrophysiology and in vivo recording deliver high-resolution functional data; and organoid culture approaches, both scaffold-based and scaffold-free, offer self-organizing systems that recapitulate developmental processes. Disease model segmentation concentrates efforts on Alzheimer's, epilepsy, Parkinson's, and stroke, where mechanistic understanding and unmet therapeutic need drive the creation of specialized assays and maturation protocols. Integrating these segmentation lenses allows stakeholders to map technological investments to specific application needs and end-user expectations, supporting targeted development and commercialization strategies.

Delineating regional strengths, regulatory nuances, and innovation ecosystems that determine strategic entry points and collaborative pathways across global markets

Regional dynamics are central to strategic positioning because innovation ecosystems, regulatory climates, and manufacturing capacity vary substantially across geographic markets. In the Americas, strong translational research infrastructure, dense networks of clinical trial sites, and a mature biotech financing environment support rapid progression from discovery to early clinical validation. This region also benefits from established biomanufacturing capabilities and a large pool of experienced neuroscientists, which together facilitate partnerships between industrial and academic stakeholders and the scaling of prototype platforms into validated services.

In Europe, Middle East & Africa, regulatory harmonization efforts, growing investment in specialized centers of excellence, and progressive ethical frameworks have created favorable conditions for collaborative research and public-private partnerships. Several jurisdictions emphasize standards for reproducibility and data sharing, which encourages multicenter validation studies and protocol standardization. Additionally, regional manufacturing clusters focused on precision instrumentation and microfabrication contribute to shorter supply chains for equipment and device components.

The Asia-Pacific region exhibits rapid capacity expansion driven by increasing domestic R&D investment, growing clinical trial activity, and strategic government support for advanced biotechnologies. Local talent pools in engineering and stem cell biology enable innovation in biofabrication and organoid culture methodologies. Moreover, a competitive manufacturing base offers opportunities for cost-effective production of reagents and instrumentation, although stakeholders must navigate heterogeneous regulatory regimes and variable market access pathways. Understanding these regional nuances enables organizations to align go-to-market strategies, partnership models, and supply chain design with localized strengths and constraints.

Evaluating competitive strategies, platform differentiation, partnership models, and innovation tactics that determine leadership and scalability in the sector

Competitive dynamics among companies in the human brain model space center on platform differentiation, service breadth, and the ability to demonstrate translational relevance through validation studies and external collaborations. Leading organizations emphasize modular platforms that allow customers to configure models by disease focus, analytical readout, and throughput, thereby addressing diverse research needs across academic and commercial users. Strategic alliances with academic centers and clinical consortia frequently serve as credibility-building mechanisms, enabling firms to benchmark platform performance against established biological endpoints.

Commercial strategies vary from product-centric supply of consumables and instrumentation to service-oriented models that deliver end-to-end assay execution and data interpretation. Firms that successfully combine proprietary assays with robust data pipelines and interpretive analytics create higher switching costs and foster long-term client relationships. Intellectual property strategies typically protect core platform technologies while maintaining interoperability through standardized data formats and validated interfaces, which facilitates ecosystem adoption without isolating collaborators.

In addition, companies are increasingly leveraging open innovation approaches to accelerate algorithm development and phenotypic interpretation, while selectively protecting hardware or wet-lab process innovations. Strategic M&A activity and targeted partnerships enable firms to rapidly expand geographic presence, augment technical capabilities, and gain access to clinical or regulatory expertise. For leadership teams, the imperative is to balance rapid commercialization with rigorous external validation, ensuring that service quality and scientific credibility scale in tandem with commercial ambitions.

Implementing resilient procurement, collaborative validation, modular product architectures, and cross-disciplinary talent strategies to accelerate adoption and de-risk development

Leaders should adopt a set of actionable initiatives that align technological capability with organizational objectives and market realities. First, prioritize supply chain resilience by establishing dual-sourcing strategies for critical reagents and components, qualifying regional suppliers, and creating contingency inventories to minimize disruption. This tactical shift reduces operational risk and allows R&D timelines to remain predictable despite external shocks.

Second, pursue collaborative validation programs with academic and clinical partners to accelerate platform acceptance. These programs should emphasize reproducibility, standardized endpoints, and open data-sharing agreements that preserve intellectual property while enabling independent verification. By doing so, organizations can build credibility with regulators and end users while accelerating adoption across translational pipelines.

Third, invest in modular product architectures that enable customers to combine high-throughput compatible formats with functionally mature, physiologically relevant systems. Complement hardware investments with robust software for data capture and analysis, ensuring that experimental complexity translates into actionable insights. Moreover, actively engage regulatory affairs expertise early in development to align assay qualification with anticipated submission requirements.

Finally, cultivate talent across disciplines by integrating engineers, stem cell biologists, computational scientists, and regulatory specialists into cross-functional teams. This human capital strategy fosters rapid iteration, supports method standardization, and facilitates commercialization pathways. Taken together, these recommendations offer a pragmatic roadmap for organizations seeking to convert technical promise into sustainable competitive advantage.

Describing a rigorous mixed-methods research approach integrating expert interviews, literature and patent review, technology readiness assessments, and validation workshops

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with a cross-section of stakeholders, encompassing senior scientists in academia, R&D leaders in pharmaceutical and biotechnology companies, heads of specialized contract research organizations, instrumentation developers, and regulatory subject-matter experts. These conversations provided insight into technology adoption drivers, validation requirements, and procurement timelines from multiple vantage points.

Secondary research involved systematic review of peer-reviewed literature, patent filings, regulatory guidance documents, technical white papers, and conference proceedings to chart the evolution of methodologies and identify emerging best practices. Technology readiness assessments were conducted to evaluate maturational trajectories for specific platforms, and patent landscaping informed competitive positioning and freedom-to-operate considerations. Data triangulation methods reconciled disparate inputs and highlighted consensus areas as well as persistent gaps requiring further investigation.

To ensure analytical transparency, findings were validated through advisory workshops with external experts and cross-checked against available protocol repositories and reproducibility studies. Limitations were acknowledged where proprietary data remained inaccessible or where nascent technologies lacked long-term validation records. Ethical compliance was integral throughout the research process, with interview protocols and data handling designed to preserve confidentiality and respect intellectual property boundaries.

Synthesizing strategic imperatives and operational priorities that determine which organizations will translate human brain model innovation into sustainable clinical and commercial value

In conclusion, human brain models represent a transformative set of tools that are reshaping how neuroscience questions are addressed and how therapeutic strategies are de-risked prior to clinical development. The field is characterized by rapid technological convergence, evolving regulatory expectations, and shifting commercial models that reward demonstrable translational relevance. Stakeholders who invest in validation, interoperability, and supply chain resilience will be best positioned to translate platform advances into clinically meaningful outcomes.

Strategic choices made today-around platform modularity, partnership structures, regional engagement, and talent acquisition-will determine which organizations capture long-term value as the ecosystem matures. While challenges remain, including standardization, reproducibility, and regulatory alignment, the cumulative progress across biofabrication, organoid culture, microfluidics, and computational modeling creates a coherent pathway toward more predictive and human-relevant research systems. As adoption spreads, success will hinge on cross-sector collaboration, disciplined operational execution, and a consistent focus on scientifically rigorous validation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Brain Models Market, by Disease Model

  • 8.1. Alzheimer's
  • 8.2. Epilepsy
  • 8.3. Parkinson's
  • 8.4. Stroke

9. Human Brain Models Market, by Technology

  • 9.1. Biofabrication
  • 9.2. Microfluidics
    • 9.2.1. Droplet Microfluidics
    • 9.2.2. Organ-on-Chip
  • 9.3. Neural Interface
    • 9.3.1. In Vitro Electrophysiology
    • 9.3.2. In Vivo Recording
  • 9.4. Organoid Culture
    • 9.4.1. Scaffold-Based
    • 9.4.2. Scaffold-Free

10. Human Brain Models Market, by Application

  • 10.1. Drug Discovery
    • 10.1.1. High Throughput Screening
    • 10.1.2. Lead Optimization
  • 10.2. Neuroscience Research
    • 10.2.1. Alzheimer's Research
    • 10.2.2. Parkinson's Research
    • 10.2.3. Stroke Studies
  • 10.3. Personalized Medicine
  • 10.4. Toxicology Testing

11. Human Brain Models Market, by End User

  • 11.1. Academia
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharma & Biotech
    • 11.4.1. Large Pharma
    • 11.4.2. Small & Mid-Size Biotech

12. Human Brain Models Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Brain Models Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Brain Models Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Brain Models Market

16. China Human Brain Models Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3D Systems, Inc.
  • 17.6. Anatomy Warehouse, LLC
  • 17.7. Brainlab AG
  • 17.8. EISCO Scientific
  • 17.9. ESP Models
  • 17.10. GE HealthCare Technologies Inc.
  • 17.11. Global Plastics, Inc.
  • 17.12. GPI Anatomicals
  • 17.13. Koninklijke Philips N.V.
  • 17.14. Materialise NV
  • 17.15. Medtronic plc
  • 17.16. Organovo Holdings, Inc.
  • 17.17. Scientific Accessories, Inc.
  • 17.18. Siemens Healthineers AG
  • 17.19. SmartLabs Education Ltd.
  • 17.20. Stratasys Ltd.
  • 17.21. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN BRAIN MODELS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN BRAIN MODELS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 216. GCC HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 225. GCC HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GCC HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 227. GCC HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 252. G7 HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 261. G7 HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. G7 HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 263. G7 HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 264. NATO HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. NATO HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 273. NATO HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. NATO HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 275. NATO HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)